Hashizume, M <br/><br/>
IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-alpha and IL-17.  [electronic resource] 

 -  Rheumatology (Oxford, England)  Nov 2008 
 - 1635-40 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1462-0332 
<br/><br/><label>Standard No.: </label>10.1093/rheumatology/ken363  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibodies, Monoclonal--pharmacology<br/>Antibodies, Monoclonal, Humanized<br/>Arthritis, Rheumatoid--metabolism<br/>Blotting, Western--methods<br/>Cell Proliferation--drug effects<br/>Cells, Cultured<br/>Fibroblasts<br/>Flavonoids--pharmacology<br/>Humans<br/>Immunohistochemistry<br/>Interleukin-17--pharmacology<br/>Interleukin-1beta--pharmacology<br/>Interleukin-6--metabolism<br/>Mitogen-Activated Protein Kinase Kinases--antagonists & inhibitors<br/>Phosphorylation--drug effects<br/>RANK Ligand--analysis<br/>RNA, Messenger--analysis<br/>Receptor Activator of Nuclear Factor-kappa B--metabolism<br/>Receptors, Interleukin-6--antagonists & inhibitors<br/>Recombinant Proteins--pharmacology<br/>Reverse Transcriptase Polymerase Chain Reaction--methods<br/>STAT3 Transcription Factor--metabolism<br/>Sesquiterpenes--pharmacology<br/>Signal Transduction--physiology<br/>Stimulation, Chemical<br/>Synovial Membrane--drug effects<br/>Tumor Necrosis Factor-alpha--pharmacology